In prostate cancer, prostate-specific membrane antigen (PSMA) has been successfully targeted with [177Lu-PSMA-617], improving survival in metastatic cases (ClinicalTrials.gov Identifier: NCT03511664). This evidence concerns the gene FOLH1 and prostate carcinoma.